Clinical trials: BPD
Respiratory Distress Syndrome, Newborn, Premature Birth
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required…
- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Trial name
- NCT00215540
- Testing
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Windtree Therapeutics
Bipolar Disorder
Bipolar Disorder in Late Life
The purpose of this study is to look at certain structural changes in the brain in people with bipolar disorder or those with a history of Bipolar disorder.
- Trial name
- BPD (NCT00787930)
- Testing
- Valproic Acid
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Duke University
Borderline Personality Disorder
Cognitive Reappraisal Training for Borderline Personality
Previous work by the study group convinced the study team to pursue development of focused cognitive reappraisal training as a novel approach to treatment of BPD, either as stand-alone treatment or in concert with evidence-based…
- Trial name
- BPD (NCT04967222)
- Testing
- Cognitive Reappraisal by Distancing, Control Downregulate Condition
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Borderline Personality Disorder, Major Depressive Disorder
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
- Trial name
- NCT05399498
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Bipolar Disorder, Alcohol Use Disorder
Ondansetron for Bipolar Disorder and Alcohol Use Disorders
The purpose of the study is to determine if ondansetron, as an add-on therapy, is associated with reduced depressive symptoms and alcohol use in outpatients with bipolar disorder (BPD), cyclothymic disorder, schizoaffective…
- Conditions
- Bipolar Disorder, Alcohol Use Disorder, Dual Diagnosis
- Trial name
- NCT02082678
- Testing
- Ondansetron
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Texas Southwestern Medical Center
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome
The Budesonide in Babies (BiB) Trial
This is a Phase 3, randomized, masked, active-controlled, multicenter trial designed to determine whether early intratracheal administration of a combination of budesonide with surfactant, as compared to surfactant alone, will…
- Conditions
- Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
- Trial name
- BiB (NCT04545866)
- Testing
- budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
- Where
- 19 sites in United States
- Volunteers
- 642 people
- Sponsor
- NICHD Neonatal Research Network
Bronchopulmonary Dysplasia, Neurally Adjusted Ventilatory Assist
NAVA vs. CMV Crossover in Severe BPD
This prospective, unblinded, pilot randomized cross-over trial of 2 modes of mechanical ventilation will compare measures of pulmonary mechanics, respiratory gas exchange, and patient comfort between conventional flow triggered…
- Conditions
- Bronchopulmonary Dysplasia, Neurally Adjusted Ventilatory Assist, Mechanical Ventilation
- Trial name
- NCT04821453
- Testing
- NAVA, CMV
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital of Philadelphia
Borderline Personality Disorder
Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)
The Primary objective of this study is to evaluate Seroquel XR in the treatment of borderline personality disorder (BPD). As in many initial randomized control trials, the study will be of relatively short duration - 8 weeks - to…
- Trial name
- NCT00880919
- Testing
- quetiapine extended-release
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- University of Minnesota
Borderline Personality Disorder
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
- Trial name
- NCT04186403
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Respiratory Syncytial Virus Infections
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
The SYNAGIS Registry was carried out in order to gather comprehensive real-world data on the use of palivizumab in children at high risk for serious respiratory syncytial virus (RSV) disease.
- Trial name
- NCT01155193
- Volunteers
- 30,804 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Borderline Personality Disorder
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
- Trial name
- NCT04932291
- Testing
- vafidemstat
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 211 people
- Sponsor
- Oryzon Genomics S.A.
Bronchopulmonary Dysplasia
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
This phase 3, multi-center, double blind, placebo-controlled, randomized clinical trial will attempt to demonstrate if preterm infants who require mechanical ventilation and/or positive pressure support at any point during days 5…
- Trial name
- NCT00931632
- Testing
- Inhaled Nitric Oxide
- Where
- 33 sites in United States, Canada
- Volunteers
- 451 people
- Sponsor
- Mallinckrodt
Healthy, Cystic Fibrosis (CF)
MRI for Non-Invasive Imaging in Neonates and Children
The purpose of this study is to develop rapid MRI techniques for imaging the lung with hyperpolarized helium-3 gas as an inhaled contrast agent.
- Conditions
- Healthy, Cystic Fibrosis (CF), Asthma, Bronchopulmonary Dysplasia (BPD)
- Trial name
- NCT02163681
- Testing
- Hyperpolarized Helium-3 MRI of the chest
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Bronchopulmonary Dysplasia
Effect of Synchronized vs. Continuous HFNC Using NAVA on WOB in Infants With BPD
Patients will be randomized to begin the study with either NAVA-synchronized or continuous HFNC. Each patient will receive two 15-minute trials at different levels of continuous HFNC and two 15-minute trials at corresponding…
- Trial name
- NCT04274192
- Testing
- Synchronized HFNC at 6 liters per minute (LPM), Continuous HFNC at 6 liters per minute (LPM), Synchronized HFNC at 8 liters per minute (LPM)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Borderline Personality Disorder, Self-Injurious Behavior
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
Self-Injurious Behavior (SIB) is a dangerous and common symptom in Borderline Personality Disorder (BPD) patients. Approximately 70% of patients with BPD engage in SIB at some point, compared to 17.5% of patients with other…
- Trial name
- NCT00539188
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Bronchopulmonary Dysplasia
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
This study will describe the safety of furosemide in premature infants at risk of bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics (PK) of furosemide. Funding Source - FDA OOPD
- Trial name
- NCT02527798
- Testing
- Furosemide Cohort 1, Furosemide Cohort 2, Furosemide Cohort 3
- Where
- 21 sites in United States
- Volunteers
- 82 people
- Sponsor
- University of North Carolina, Chapel Hill
Borderline Personality Disorder
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.
- Trial name
- NCT00275301
- Testing
- olanzapine
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Bronchopulmonary Dysplasia
Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia
The purpose of this study is to determine if late doses of Infasurf surfactant given when patients are receiving inhaled nitric oxide will interact to improve surfactant function and increase survival without BPD in treated…
- Trial name
- TOLSURF (NCT01022580)
- Testing
- Infasurf surfactant (ONY, Inc.)
- Where
- 21 sites in United States
- Volunteers
- 511 people
- Sponsor
- Roberta Ballard
Bronchopulmonary Dysplasia
Inhaled Tobramycin in BPD
This study is an open-label, phase 1, sequential dose escalation trial seeking to establish preliminary tolerability, efficacy, and pharmacokinetic data for up to 4 different doses of inhaled tobramycin administered to very…
- Trial name
- NCT04560179
- Testing
- Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Erik Allen Jensen
Severe Bronchopulmonary Dysplasia
Aerosolized Albuterol Use in Severe BPD
Currently several dose schedules of Albuterol are administered via nebulization to infants in the neonatal and infant intensive care unit (N/IICU).
- Trial name
- NCT02766673
- Testing
- Albuterol Sulfate, Sterile Saline
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital of Philadelphia